Effect of Technetium[99Tc]Methylenediphosphonate Injection Combined with Methotrexate and Hydroxychloroquine Sulfate on Erythrocyte Sedimentation Rate and Rheumatoid Factor in Patients with Rheumatoid Arthritis
Objective:To explore the effect of Technetium[99Tc]Methylenediphosphonate Injection combined with Methotrexate and Hydroxychloroquine Sulfate on erythrocyte sedimentation rate(ESR)and rheumatoid factor(RF)in patients with rheumatoid arthritis(RA).Method:A total of 66 RA patients treated in Fuzhou Municipal Hospital from April 2021 to May 2022 were selected and randomly divided into two groups,with 33 patients in each group.The control group was treated with Methotrexate and Hydroxychloroquine Sulfate,and the observation group was treated with Technetium[99Tc]Methylenediphosphonate Injection combined with Methotrexate and Hydroxychloroquine Sulfate.Both groups continued to receive treatment for 3 months.The clinical efficacy,ESR and RF,inflammatory factor levels,rheumatoid arthritis activity(DAS28)score,symptom improvement,visual analogue scale(VAS)score,and adverse reactions in two groups were compared.Result:The total clinical effective rate in the observation group was 96.97%(32/33),which was higher than 75.76%(25/33)in the control group,with statistical difference(P＜0.05).After treatment,interleukin-6(IL-6)(3.52±0.47)pg/mL,tumor necrosis factor-α(TNF-α)(3.91±1.02)pg/mL,C reactive protein(CRP)(12.33±5.15)mg/L,RF(31.62±15.16)IU/mL,ESR(25.89±10.69)mm/h in the observation group,which were all lower than(8.03±1.02)pg/mL,(7.94±2.54)pg/mL,(16.38±6.41)mg/L,(42.98±16.87)IU/mL,(35.92±11.84)mm/h in the control group,joint swelling number(2.01±0.45),joint tenderness number(4.15±1.31),which were less than(4.05±1.56)and(6.14±2.02)in the control group,stiffness time(25.56±9.13)minutes in the observation group,which was shorter than(32.85±11.85)minutes in the control group,average grip strength of both hands(12.03±2.91)kPa in the observation group,which was higher than(9.51±1.05)kPa in the control group,DAS28 score(2.02±0.74)points,VAS score(2.12±0.29)points in the observation group,which were lower than(4.38±1.29)and(4.15±0.57)points in the control group,with statistically significant differences(P＜0.05).The comparison of incidence of adverse reactions in two groups was not statistical different(P＞0.05).Conclusion:Technetium[99Tc]Methylenediphosphonate Injection combined with Methotrexate and Hydroxychloroquine Sulfate has a better effect in RA patients,which can reduce inflammatory factor levels,improve clinical symptoms and joint range of motion,alleviate pain,and there is no increase in adverse reactions.
万方数据
